Navigation Links
Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart Failure Patients
Date:7/30/2008

SAN FRANCISCO, July 30 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), today announced that Mayo Clinic has initiated a Phase Ib, double-blind, placebo-controlled clinical study of CD-NP, a novel chimeric natriuretic peptide, in development for the treatment of acute decompensated heart failure.

The primary objective of the study is to assess renal, neurohumoral and non-invasive hemodynamic physiologic parameters of intravenous infusions of CD-NP in patients with heart failure. Key assessments include glomerular filtration rate, tubular function, renal plasma flow, urine output, mean arterial pressure, and various biomarkers. The trial is expected to enroll 27 heart failure patients.

"We are delighted that dosing has begun in this important Phase Ib study of CD-NP in patients with heart failure," said Peter Strumph, Chief Executive Officer of Nile. "This Mayo sponsored study, which is the fourth clinical study of CD-NP, will enable us to continue to build on our understanding of the clinical effects of CD-NP."

Results from Nile's Phase Ia study in 22 healthy volunteers were consistent with several pre-clinical findings, including that CD-NP was associated with increased levels of plasma cGMP, preserved renal function, increased natriuresis and diuresis with minimal effect on mean arterial pressure.

In parallel with Mayo's Phase Ib study, Nile is currently dosing Phase Ib and Phase IIa studies of CD-NP in heart failure patients. The primary objective of the Phase Ib study is to assess the safety and tolerability of intravenous infusions of CD-NP in patients with heart failure. The primary objective of the Phase IIa study is to assess hemodynamic effects of intravenous infusions of CD-NP in pati
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... , May 27, 2015 OpportunityAnalyzer: Sepsis - ... Sepsis patients suffer from a series of diverse complications ... in the blood or tissues, which cause a rapidly ... to mortality rates near 50% depending on disease severity. ... healthcare systems of the global marketplace, which for the ...
(Date:5/27/2015)... -- PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - ... Event-Driven Update Summary The lupus therapeutics ... the only drug that has gained marketing approval for ... patients, uptake has remained low, but due to its ... lupus market in terms of value and is currently ...
(Date:5/27/2015)... 27, 2015 Research ... addition of the  "Asia Pacific Ultrasound Devices ... - 2019)"  company profile to their ... , ,Ultrasound is a type of imaging. ... at body parts and structures inside the ...
Breaking Medicine Technology:OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 3OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 4PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update 2PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update 3Asia Pacific Ultrasound Devices Market Report 2015 - Growth, Trends And Forecasts 2014 - 2019 2
... Meg Porfido, former chief human resources officer for Level ... Directors for Kaiser Foundation Hospitals and Kaiser Foundation Health ... to our Board will further diversify the outstanding talents ... George C. Halvorson, chairman and chief executive officer of ...
... 2011 Varian Medical Systems (NYSE: VAR ... system vendors in a 2011 performance report released last ... monitoring and reporting on the performance of healthcare technology ... a range of clinical, administrative, and financial activities in ...
Cached Medicine Technology:Kaiser Foundation Hospitals and Health Plan Appoints Meg Porfido to Its Board of Directors 2Kaiser Foundation Hospitals and Health Plan Appoints Meg Porfido to Its Board of Directors 3Varian Medical Systems' ARIA Ranked No. 1 in 2011 KLAS Report on Oncology IT Vendors 2Varian Medical Systems' ARIA Ranked No. 1 in 2011 KLAS Report on Oncology IT Vendors 3
(Date:5/27/2015)... 2015 Continuing its commitment to finding ... in the community, SmartPractice® donated $25,000 to ... Lincoln). SmartPractice Vice President of Human Resources Meg Mosher ... $25,000 check to Paulla Miller, Sherry Gage, Dr. Linda ... Research Center on April 30. The center is located ...
(Date:5/27/2015)... Austin, Texas (PRWEB) May 27, 2015 ... margins are getting tighter, it can be challenging for ... technology for cutting edge treatments. , Austin-based ... problem, with minimally invasive, mobile medical therapies for clinically ... medical portfolio with the acquisition of Laser Ventures, ...
(Date:5/27/2015)... May 27, 2015 The new ... include: Why investors should consider oil and gas investing, ... why wells are drilled, industry news, IRA investing, definitions ... 32 years of knowledge and experience is now in ... community to be able to access 24 hours a ...
(Date:5/27/2015)... In support of a new ... the Journal of American Geriatrics Society about the link ... Bedford Commons OB-GYN P.A . is reiterating the nutritional ... , To examine the relationship between diet soda ... Longitudinal Study of Aging (SALSA) tracked the soda consumption ...
(Date:5/27/2015)... ABILENE, Texas (PRWEB) May 27, 2015 ... addition of three FDA-approved dermal filler treatments in Abilene, ... designed to reduce the appearance of glabellar lines, better ... lines. Belotero Balance® is designed to treat smoker’s ... mouth to the chin, while Radiesse® improves the appearance ...
Breaking Medicine News(10 mins):Health News:SmartPractice Donates $25,000 to HonorHealth Breast Health and Research Center 2Health News:HealthTronics Invests in Additional Mobile Medical Technologies As Cost Efficient Solution for Hospitals, Doctors 2Health News:HealthTronics Invests in Additional Mobile Medical Technologies As Cost Efficient Solution for Hospitals, Doctors 3Health News:Carson Energy Launches Next Generation Investor Website 2Health News:Recent Study About the Link Between Diet Sodas and Abdominal Fat Reinforces Bedford Commons OB-GYN's Recommendation to Drink Plenty of Water 2Health News:The MedSpa at Hendrick Introduces Xeomin®, Belotero Balance® and Radiesse® Injectables 2
... perform with, it would be British band Coldplay. ... and that's why he would give an arm and a leg ... Timberlake knows just who he wants to jam with - Gwyneth ... so I'd love to do a duet with them - especially ...
... systems have been deployed worldwide to provide early detection ... ,New methods that improve the overall detection capabilities ... However, most surveillance systems do not hold up when ... caused by public-health crises and major public events, such ...
... and Hull York Medical School has confirmed a link between ... is a vitamin that comes from vegetables such as spinach ... sunflower seeds as well as liver are rich sources of ... to bread or flour will decrease the number of babies ...
... shows that the work intended for global health is ... ,The research was conducted by a UW team including ... the School of Public Health and Community Medicine; Jennifer ... Weatherford, finance and administration director of the Department of ...
... of alcohol has found that a high percentage of ... youth .Many high school students consume alcohol both regularly ... sources of alcohol, individuals who illegally provide alcohol to ... ,Many types of social sources of alcohol are used ...
... review shows how nicotine patches can double ... that the antidepressants bupropion and nortriptyline aid long-term ... (e.g. fluoxetine) do not. ,Yet another ... UK by NICE), increased the odds of successful ...
Cached Medicine News:Health News:Global Health Enriching the States Economy 2Health News:Underage Youth Get Alcohol from Social Sources 2Health News:Underage Youth Get Alcohol from Social Sources 3
... STaK-Chex, a whole blood assayed hematology ... five-part white cell differential available with the ... unique product has 14-day open-vial stability, 105-day ... normal and high levels. The 4.0ml pierceable ...
Antelys Peek Lumbar Technologies provides a range of varied heights and angles to correct lumbar lordosis and the associated sagital balance....
Spectrum Dynamics empowers Nuclear Imaging with the SmartR Technology,of the D-SPECT Cardiac Imaging System. The D-SPECT is powered by BroadView Technology to provide unprecedented throughput, whil...
For immediate disabling...
Medicine Products: